[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352458-105":59,"doc-detail-352458-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","denosumab-plus-immune-checkpoint-inhibitors-in-bone-metastases-from-solid-tumors-narrative-review","Denosumab Plus Immune Checkpoint Inhibitors in Bone Metastases From Solid Tumors - Narrative Review","","Bone metastases are a frequent and devastating complication of advanced solid tumors, reducing patients’ quality of life and worsening prognosis. Immune checkpoint inhibitor (ICI) plus bone-targeted therapy is emerging as a strategy to improve outcomes. Denosumab, a RANKL-targeting antibody, suppresses osteoclast-driven bone resorption and reshapes the immune microenvironment. By limiting immunosuppressive factors and improving vascular integrity, it supports immune-cell infiltration. ICIs restore T-cell activity and, together, may synergize via T-cell reinvigoration and enhanced dendritic-cell maturation and antigen presentation. This narrative review summarizes preclinical and clinical evidence, biomarkers, and challenges for optimizing patient selection and therapeutic paradigms, including ongoing studies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/denosumab-plus-immune-checkpoint-inhibitors-in-bone-metastases-from-solid-tumors-narrative-review/352458/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/denosumab-plus-immune-checkpoint-inhibitors-in-bone-metastases-from-solid-tumors-narrative-review/352458.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are bone metastases especially severe in advanced solid tumors?","Question",{"text":113,"@type":114},"Bone metastases are common and severe, causing major impacts on patients’ quality of life and prognosis, with frequent complications such as pain and skeletal deterioration.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does denosumab work in bone metastases?",{"text":118,"@type":114},"Denosumab targets RANKL to inhibit osteoclast-mediated bone resorption and prevent skeletal-related events. It can also modulate the immune microenvironment by reducing immunosuppressive factors and improving conditions for immune-cell infiltration.",{"name":120,"@type":111,"acceptedAnswer":121},"What immune effect do ICIs provide, and how might synergy with denosumab occur?",{"text":122,"@type":114},"ICIs restore T-cell activity by overcoming tumor-induced immune suppression. Synergy is suggested through reinvigorated T-cell function and enhanced dendritic-cell maturation and antigen-presentation capacity, amplifying adaptive immune responses against metastatic bone tumors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352458,1790146866,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Review Article  \n\n| Denosumab Plus Immune Checkpoint Inhibitors in Bone Metastases From Solid Tumors\u003Cbr>Na Wang1,2, Feixue Song1, Xiangkai Li2, and Hao Chen3 | Cancer Control Volume 33: 1–11 © The Author(s) 2026 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/10732748261427063](DOI: 10.1177/10732748261427063)\u003Cbr>[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Abstract\u003Cbr>Bone metastases are a common and devastating complication of advanced solid tumors, significantly impairing patients’quality of life and prognosis. Immune checkpoint inhibitor (ICI) plus bone-targeted therapies have emerged as a promising strategy to improve outcomes in patients with bone metastases. Denosumab, a fully human mAb targeting RANKL, can inhibit osteoclast-mediated bone resorption and prevent skeletal-related events. Beyond its direct bone remodeling activity, denosumab can also modulate the immune microenvironment, enhance anti-tumor immunity by reducing the release of immunosuppressive factors into the bone milieu, and improve vascular integrity within previously damaged bone tissue to facilitate immune cell infiltration into the metastatic niches. ICIs restore T-cell activity by overcoming tumorinduced immune suppression, thereby enabling more effective anti-tumor responses. Emerging evidence have suggested a potential synergy of denosumab plus ICIs, mechanistically by reinvigorating T-cell function and promoting maturation and antigen-presenting capacity of dendritic cells to further amplify adaptive immune response against metastatic bone tumors. The present narrative review summarizes the preclinical and clinical findings on this combination and discusses potential biomarkers and current challenges for the optimization of patient selection and therapeutic paradigm. Besides, we briefly overview current ongoing studies that investigate the potential antitumor synergy with denosumab plus ICIs in bone metastases.\u003Cbr>Plain Language Summary\u003Cbr>Bone metastases are a frequent and serious complication in patients with advanced solid cancers, often causing pain, fractures, and reduced quality of life. Combining immune checkpoint inhibitors (ICIs) with bone-targeted therapies has emerged as a potential approach to improve outcomes for these patients. Denosumab, an antibody that blocks RANKL, can prevent bone loss and skeletal-related events by reducing the activity of bone-resorbing cells. Beyond protecting bone, denosumab may also help the immune system fight cancer by improving the bone environment, reducing immunosuppressive factors, and supporting immune cell infiltration into metastatic sites. ICIs work by restoring the activity of T cells, helping the body mount stronger anti-tumor responses. Emerging evidence suggested that combining denosumab with ICIs could enhance the immune attack on cancer in the bone, potentially by boosting Tcell function and improving how immune cells recognize and respond to tumor antigens. This review summarizes the current preclinical and clinical evidence on this combination, discusses potential biomarkers and challenges, and ongoing studies aimed at optimizing treatment strategies in bone metastases. |  |\n| 1Department of Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China 2School of Life Sciences, Lanzhou University, Lanzhou, Gansu Province, China\u003Cbr>3Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China\u003Cbr>Corresponding author:\u003Cbr>Hao Chen, Department of Tumor Surgery, Lanzhou University Second Hospital, No. 82 Cuiyingmen Lanzhou, Lanzhou, Gansu Province 730030, China.\u003Cbr>Email: [ery_chenh@lzu.edu.cn](ery_chenh@lzu.edu.cn) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativeco","cbCaimlkevbBxLp8","https://ap.wps.com/l/cbCaimlkevbBxLp8","pdf",4043972,11,"English","# Abstract\n## Plain Language Summary\n# Introduction\n## Bone metastases and treatment landscape\n## Bone microenvironment interactions and immune suppression","[{\"question\":\"Why are bone metastases especially severe in advanced solid tumors?\",\"answer\":\"Bone metastases are common and severe, causing major impacts on patients’ quality of life and prognosis, with frequent complications such as pain and skeletal deterioration.\"},{\"question\":\"How does denosumab work in bone metastases?\",\"answer\":\"Denosumab targets RANKL to inhibit osteoclast-mediated bone resorption and prevent skeletal-related events. It can also modulate the immune microenvironment by reducing immunosuppressive factors and improving conditions for immune-cell infiltration.\"},{\"question\":\"What immune effect do ICIs provide, and how might synergy with denosumab occur?\",\"answer\":\"ICIs restore T-cell activity by overcoming tumor-induced immune suppression. Synergy is suggested through reinvigorated T-cell function and enhanced dendritic-cell maturation and antigen-presentation capacity, amplifying adaptive immune responses against metastatic bone tumors.\"}]","Denosumab Plus Immune Checkpoint Inhibitors in Bone Metastases From Solid Tumors - Narrative Review | PDF",1790099776,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78fdf639c8ee5a9ce266921449e7ef62.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ab8e2ec9df4c39c010f8b38f2e2b566.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dae83b336bc444424bdd114e5d4132c4.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa2c21cc7833fc2570ac25776910e244.webp",980,1306]